265 related articles for article (PubMed ID: 30056976)
1. Introduction to expert opinion on endocrine complications of new anticancer therapies.
Castinetti F; Borson-Chazot F
Ann Endocrinol (Paris); 2018 Oct; 79(5):535-538. PubMed ID: 30056976
[TBL] [Abstract][Full Text] [Related]
2. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Ann Endocrinol (Paris); 2018 Oct; 79(5):591-595. PubMed ID: 30056975
[TBL] [Abstract][Full Text] [Related]
3. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
[TBL] [Abstract][Full Text] [Related]
4. Expert opinions on endocrine toxicity induced by new anticancer therapies: Precautions to be taken in performing and interpreting hormonal assays under immunotherapy.
Lahlou N; Raverot V
Ann Endocrinol (Paris); 2018 Oct; 79(5):550-554. PubMed ID: 30149892
[TBL] [Abstract][Full Text] [Related]
5. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
6. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines].
Castinetti F; Borson-Chazot F
Bull Cancer; 2019 May; 106(5):492-496. PubMed ID: 30981462
[TBL] [Abstract][Full Text] [Related]
8. [Endocrinopathies induced by immune checkpoint inhibitors].
Jaafar J; Mavromati M; Philippe J
Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion on immunotherapy induced diabetes.
Smati S; Buffier P; Bouillet B; Archambeaud F; Vergès B; Cariou B
Ann Endocrinol (Paris); 2018 Oct; 79(5):545-549. PubMed ID: 30126628
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
14. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
[TBL] [Abstract][Full Text] [Related]
15. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review.
Gebauer J; Higham C; Langer T; Denzer C; Brabant G
Endocr Rev; 2019 Jun; 40(3):711-767. PubMed ID: 30476004
[TBL] [Abstract][Full Text] [Related]
18. Endocrine complications of cancer immunotherapy.
Król A; Gawlik T; Jarząb B
Endokrynol Pol; 2018; 69(6):722-733. PubMed ID: 30618030
[TBL] [Abstract][Full Text] [Related]
19. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
Di Giacomo AM; Biagioli M; Maio M
Semin Oncol; 2010 Oct; 37(5):499-507. PubMed ID: 21074065
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy is cancer treatment with a novel side-effect profile].
Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
